Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

NCT07199296 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Orelabrutinib
DRUG: Rituximab (R)
DRUG: BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
DRUG: orelabrutinib maintenance

Sponsor

Ruijin Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]